scholarly journals The use of sildenafil in severe early-onset fetal growth restriction: a case report and review of current literature

2018 ◽  
Vol 3 (3) ◽  
Author(s):  
Geoffrey H Gordon ◽  
Danielle M Berdahl ◽  
Kara K Hoppe ◽  
Kathleen M Antony
Keyword(s):  
Case Report ◽  
Fetal Growth ◽  
Current Literature ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Growth Restriction

641 Fetal growth restriction and risk of intrapartum cesarean among women with early onset preeclampsia

2021 ◽  
Vol 224 (2) ◽  
pp. S403
Author(s):  
Emily N. Flagler ◽  
Erin M. Cleary ◽  
Michelle R. Petrich ◽  
Emily A. Armstrong ◽  
Patricia K. Belle ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Growth Restriction ◽  
Early Onset Preeclampsia

scholarly journals Risk stratification for early-onset fetal growth restriction in women with abnormal serum biomarkers: a retrospective cohort study

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
L. Ormesher ◽  
L. Warrander ◽  
Y. Liu ◽  
S. Thomas ◽  
L. Simcox ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Late Onset ◽  
Area Under The Curve ◽  
Maternal Serum ◽  
Serum Biomarkers ◽  
Growth Restriction ◽  
Aneuploidy Screening ◽  
Internal Validation

AbstractAbnormal maternal serum biomarkers (AMSB), identified through the aneuploidy screening programme, are frequent incidental findings in pregnancy. They are associated with fetal growth restriction (FGR), but previous studies have not examined whether this association is with early-onset (< 34 weeks) or late-onset (> 34 weeks) FGR; as a result there is no consensus on management. The aims of this study were to determine the prevalence and phenotype of FGR in women with AMSB and test the predictive value of placental sonographic screening to predict early-onset FGR. 1196 pregnant women with AMSB underwent a 21–24 week “placental screen” comprising fetal and placental size, and uterine artery Doppler. Multivariable regression was used to calculate a predictive model for early-onset FGR (birthweight centile < 3rd/< 10th with absent umbilical end-diastolic flow, < 34 weeks). FGR prevalence was high (10.3%), however early-onset FGR was uncommon (2.3%). Placental screening effectively identified early-onset (area under the curve (AUC) 0.93, 95% confidence interval (CI) 0.87–1.00), but not late-onset FGR (AUC 0.70, 95% CI 0.64–0.75). Internal validation demonstrated robust performance for detection/exclusion of early-onset FGR. In this cohort, utilisation of our proposed algorithm with targeted fetal growth and Doppler surveillance, compared with universal comprehensive surveillance would have avoided 1044 scans, potentiating significant cost-saving for maternity services.

scholarly journals Early-onset fetal growth restriction defined by only abdominal circumference is associated with perinatal mortality

2022 ◽  
Vol 226 (1) ◽  
pp. S165
Author(s):  
James D. Toppin ◽  
Miranda Long ◽  
Rick Tivis ◽  
Joseph Biggio ◽  
Frank Williams
Keyword(s):  
Perinatal Mortality ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Growth Restriction ◽  
Abdominal Circumference

scholarly journals Outcomes of pregnancies complicated by severe early-onset fetal growth restriction

2022 ◽  
Vol 226 (1) ◽  
pp. S535-S536
Author(s):  
Juliana Gevaerd Martins ◽  
Tetsuya Kawakita ◽  
Carole Barake ◽  
Lindsay Gould ◽  
Dana Baraki ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Growth Restriction

Soluble fms‐like tyrosine kinase to placental growth factor ratio in different stages of early‐onset fetal growth restriction and small for gestational age

2020 ◽  
Vol 100 (1) ◽  
pp. 119-128
Author(s):  
Pablo Garcia‐Manau ◽  
Manel Mendoza ◽  
Erika Bonacina ◽  
Carmen Garrido‐Gimenez ◽  
Antoni Fernandez‐Oliva ◽  
...  
Keyword(s):  
Growth Factor ◽  
Tyrosine Kinase ◽  
Fetal Growth ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Placental Growth Factor ◽  
Growth Restriction ◽  
Factor Ratio

scholarly journals Protect-me: a parallel-group, triple blinded, placebo-controlled randomised clinical trial protocol assessing antenatal maternal melatonin supplementation for fetal neuroprotection in early-onset fetal growth restriction

BMJ Open ◽  
2019 ◽  
Vol 9 (6) ◽  
pp. e028243 ◽  
Author(s):  
Kirsten R Palmer ◽  
Joanne C Mockler ◽  
Miranda L Davies-Tuck ◽  
Suzanne L Miller ◽  
Stacy K Goergen ◽  
...  
Keyword(s):  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Perinatal Death ◽  
Controlled Trial ◽  
Brain Mri ◽  
Randomised Clinical Trial ◽  
Growth Restriction ◽  
Cognitive Domain ◽  
Singleton Pregnancy

IntroductionFetal growth restriction (FGR) is a serious pregnancy complication, associated with increased rates of perinatal death and morbidity among survivors. Most commonly FGR results from placental insufficiency, where the placenta fails to deliver the oxygen and nutrients required for normal fetal growth. This leads to fetal oxidative stress, resulting in organ damage through lipid peroxidation. The early developing brain is particularly susceptible, such that FGR is associated with poorer neurodevelopment, witnessed as cognitive and behavioural dysfunction, and cerebral palsy. Promisingly, melatonin, a lipid soluble antioxidant is neuroprotective in animal models of FGR. We present a protocol outlining a randomised, placebo-controlled trial to explore whether antenatal maternal melatonin supplementation in pregnancies with severe, early-onset FGR can improve neurodevelopment among survivors at 2 years of age.Methods and analysesWe will recruit 336 women with a singleton pregnancy complicated by FGR between 23+0 and 31+6 weeks gestation. Participants will be randomised, stratified by gestational age, to either 30 mg melatonin per day or a visually identical placebo, continued until birth. Measures of maternal and fetal health will be collected until birth. Timing of birth will be determined by the treating clinical team in discussion with the woman. Neonatal and infant neurodevelopmental assessments will be undertaken, consisting of brain MRI at term corrected age, general movements assessment at term and 3 months’ corrected age, and Bayley Scales of Infant & Toddler Development-III and Infant Toddler Social Emotional Assessment at 2.5 years corrected age. Analyses will be on intention to treat. The primary outcome is a difference of 5 points in the cognitive domain of the Bayley-III. Secondary outcomes address maternal and fetal safety.Ethics and disseminationThis trial has Monash Health Human Research and Ethics committee approval (17-0000-583A). Findings will be disseminated through peer-reviewed publications, conference presentations and to participants.Trial registration numberACTRN12617001515381; Pre-results

scholarly journals Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction

2020 ◽  
Vol 3 (6) ◽  
pp. e205323 ◽  
Author(s):  
Anouk Pels ◽  
Jan Derks ◽  
Ayten Elvan-Taspinar ◽  
Joris van Drongelen ◽  
Marjon de Boer ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Early Onset ◽  
Growth Restriction
Sign in / Sign up

Export Citation Format

Share Document